CN116033901A - 用于治疗眼睛障碍的化合物和方法 - Google Patents

用于治疗眼睛障碍的化合物和方法 Download PDF

Info

Publication number
CN116033901A
CN116033901A CN202180056862.4A CN202180056862A CN116033901A CN 116033901 A CN116033901 A CN 116033901A CN 202180056862 A CN202180056862 A CN 202180056862A CN 116033901 A CN116033901 A CN 116033901A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
subject
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180056862.4A
Other languages
English (en)
Chinese (zh)
Inventor
D·凯利
M·帕帕迪米特里奥
C·博恩斯
E·丹尼尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OccuRx Pty Ltd
Original Assignee
OccuRx Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020901856A external-priority patent/AU2020901856A0/en
Application filed by OccuRx Pty Ltd filed Critical OccuRx Pty Ltd
Publication of CN116033901A publication Critical patent/CN116033901A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
CN202180056862.4A 2020-06-05 2021-06-03 用于治疗眼睛障碍的化合物和方法 Pending CN116033901A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2020901856A AU2020901856A0 (en) 2020-06-05 Compounds and Methods for the Treatment of Eye Disorders
AU2020901856 2020-06-05
AU2020901858A AU2020901858A0 (en) 2020-06-05 Compounds and Methods for the Treatment of Eye Disorders
AU2020901858 2020-06-05
PCT/US2021/035749 WO2021247900A1 (en) 2020-06-05 2021-06-03 Compounds and methods for the treatment of eye disorders

Publications (1)

Publication Number Publication Date
CN116033901A true CN116033901A (zh) 2023-04-28

Family

ID=78829970

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180056862.4A Pending CN116033901A (zh) 2020-06-05 2021-06-03 用于治疗眼睛障碍的化合物和方法

Country Status (11)

Country Link
US (1) US20230270703A1 (enExample)
EP (1) EP4161527A4 (enExample)
JP (1) JP2023529845A (enExample)
KR (1) KR20230024331A (enExample)
CN (1) CN116033901A (enExample)
AU (1) AU2021284380A1 (enExample)
BR (1) BR112022024728A2 (enExample)
CA (1) CA3185849A1 (enExample)
IL (1) IL298733A (enExample)
MX (1) MX2022015327A (enExample)
WO (2) WO2021247901A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022197681A1 (en) * 2021-03-17 2022-09-22 Occurx Pty Ltd Compounds for the treatment of disorders and salts and polymorphs thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6339814A (ja) * 1986-08-01 1988-02-20 Teisan Seiyaku Kk トラニラストの経口用持続性製剤
WO1997029744A1 (en) * 1996-02-15 1997-08-21 Kissei Pharmaceutical Co., Ltd. Neovascularization inhibitor
JPH09278653A (ja) * 1996-04-05 1997-10-28 Santen Pharmaceut Co Ltd 網膜疾患治療剤
EP1008347A4 (en) * 1997-04-18 2002-02-06 Kissei Pharmaceutical REMEDIES FOR PROPHYLAXIS OR TREATMENT OF DISEASES RESULTING IN EXCESSIVE PROLIFERATION OF PIGMENTAL RETINE EPITHELIAL CELLS
AU2002366641A1 (en) * 2001-12-11 2003-06-23 Fibrogen, Inc. Methods for inhibiting ocular processes
NZ592039A (en) * 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
MX2010004281A (es) * 2007-10-19 2010-09-10 Sarcode Corp Composiciones y metodos para el tratamiento de la retinopatia diabetica.
JP2011006406A (ja) * 2009-05-29 2011-01-13 Santen Pharmaceut Co Ltd トラニラストを含有する網膜疾患の予防または治療剤
WO2012068612A1 (en) * 2010-11-24 2012-05-31 Fibrotech Therapeutics Pty Ltd Methods of treating eye diseases associated with inflammation and vascular proliferation
US10780070B2 (en) * 2013-10-18 2020-09-22 The Schepens Eye Research Institute, Inc. Alpha-aminoadipate for treatment of vision loss and restoring sight

Also Published As

Publication number Publication date
IL298733A (en) 2023-02-01
BR112022024728A2 (pt) 2023-03-07
MX2022015327A (es) 2023-02-22
US20230270703A1 (en) 2023-08-31
KR20230024331A (ko) 2023-02-20
WO2021247900A1 (en) 2021-12-09
WO2021247901A1 (en) 2021-12-09
EP4161527A4 (en) 2024-06-26
CA3185849A1 (en) 2021-12-09
EP4161527A1 (en) 2023-04-12
AU2021284380A1 (en) 2023-01-19
JP2023529845A (ja) 2023-07-12

Similar Documents

Publication Publication Date Title
US8188140B2 (en) Uses of ion channel modulating compounds
RU2262933C2 (ru) Медицинские композиции, содержащие аспирин
JP6872322B2 (ja) クエン酸エステルを含有するデポ剤
JP2017515854A (ja) カスパーゼ阻害剤による慢性肝疾患の合併症の治療
JP2020521002A (ja) テトラメチルピラジンニトロン誘導体の糖尿病合併症疾患の予防と治療における応用
RU2406499C2 (ru) Профилактическое или терапевтическое средство для лечения кератоконъюнктивитных нарушений
EP3272362A1 (en) Sustained-release pharmaceutical composition
JP2014185161A (ja) シロスタゾールを含むカルボスチリル誘導体の脂肪肝治療剤
PT1905452E (pt) Agente para a prevenção ou tratamento do glaucoma
CN113453677A (zh) 用于治疗急性心房颤动的舒卡定施用
TWI870751B (zh) 心腦血管藥物及其應用
WO1996038173A1 (en) Brain edema inhibitor
AU2021284380A1 (en) Compounds and methods for the treatment of eye disorders
CN111542316A (zh) 用于治疗眼睛后段疾病的包含羟苯磺酸的眼科局部组合物
JP6490597B2 (ja) 眼の疾患および障害を治療するための方法
KR20160113720A (ko) 황 함유 모이어티를 포함하는 당 유도체 및 이의 제조 방법 및 mps iiic의 치료를 위한 이의 사용 방법
CN101015556B (zh) 窦房结If电流抑制剂与钙抑制剂的组合以及含有它的药物组合物
WO2011149012A1 (ja) イソキノリンスルホニル誘導体を有効成分として含有する網脈絡膜変性疾患の予防または治療剤、網脈絡膜変性疾患の予防または治療方法、イソキノリンスルホニル誘導体またはその医薬的に許容される塩、ならびにその使用
AU778148B2 (en) 2-aminotetralin derivatives for the therapy of glaucoma
KR20210141203A (ko) 에르도스테인 유도체 및 이를 함유하는 약학 조성물
JP2023529845A5 (enExample)
US9987368B2 (en) Pharmaceutical composition comprising polypeptide
KR20110084514A (ko) 피리딘-3-카르발데히드 ｏ-(피페리딘-1-일-프로필)-옥심 유도체를 유효 성분으로서 함유하는 망맥락막 변성 질환의 치료제
CN115557898A (zh) 一种咪唑类化合物、其中间体及应用
HK40061591A (en) Sulcardine administration for treatment of acute atrial fibrillation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination